OPTIMIZER PAS: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy (PAS)

OPTIMIZER PAS: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy (PAS)
Recruiting
18-100 years
All
Phase N/A
20 participants needed
1 Location

Brief description of study

The OPTIMIZER Smart Post-Approval Study (PAS) is a single arm open label study of 620 participants receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%.
 

Detailed description of study

The Impulse Dynamics OPTIMIZER Smart Pre-Market Application (PMA) clinical data confirmed that cardiac contractility modulation (CCM) therapy delivered with the Optimizer system improved health outcomes in patients with NYHA class III heart failure symptoms and left ventricular ejection fraction of 25-45%. CCM has shown significant improvements in quality of life measures. Six minute walk test and functional class also showed improvements in the PMA data. The post-approval study (PAS) protocol has been designed to evaluate long term safety and efficacy of the OPTIMIZER Smart in a real-world setting.

Eligible subjects will receive the OPTIMIZER Smart, which is comprised of three major components:

  1. Optimizer Smart or Optimizer
  2. Smart Mini Vesta Charger or Guardio Charger
  3. Two commercially available intravascular leads

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Heart failure
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion
 

  • ≥ 18 years of age
  • Left ventricular ejection fraction of 25-45%
  • NYHA Class III heart failure symptoms
  • Treated with guideline-directed medical therapy

Exclusion
 

  • Primary heart failure due to uncorrected mitral valve disease, or mitral valve repair or clip within 90 days of implant
  • Myocardial infarction within 90 days prior to implant
  • Prior heart transplant or ventricular assist device
  • Receiving cardiac resynchronization therapy (CRT) or has a Class I indication for CRT implantation
  • Currently participating in a cardiac investigational study at the same time

Updated on 11 Oct 2024. Study ID: 856448

Find a site

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center